A Single-centre, retrospective study to evaluate the treatment outcomes of Palbociclib in patients with HR+ metastatic breast cancer
Latest Information Update: 02 Jun 2017
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record